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Summary
Background Anaemia is a major cause of morbidity and mortality in low-income countries. Primary health-care 
workers in resource-poor settings usually diagnose anaemia clinically, but this is inaccurate. The WHO Haemoglobin 
Colour Scale (HCS) is a simple, cheap quantitative method to assess haemoglobin concentration outside of the 
laboratory. We systematically reviewed the literature to assess the accuracy of the HCS in primary care to diagnose 
anaemia, and compared this with clinical assessment.
Methods We searched the electronic databases including MEDLINE, EMBASE, SCOPUS, Web of Science, Cochrane 
library, CINAHL plus, Popline, Reproductive Health Library, and Google Scholar and regional databases up to Nov 14, 
2014, “haemoglobin colour scale” in alternative spellings published in any language. Two reviewers independently 
screened studies, extracted data, and assessed quality using the QUADAS-2 instrument. Statistical analyses were 
carried out in STATA using the bivariate model. 
Findings Of 141 records and abstracts screened, 14 studies were included. The pooled sensitivity of the HCS to 
diagnose anaemia was 80% (95% CI 68–88) compared with 52% for clinical assessment ([95% CI 36–67]; p=0·008). 
Speciﬁ city was similar between the HCS (80% [95% CI 59–91]) and clinical assessment (75% [56–88]; p=0·8250). For 
severe anaemia, diagnostic accuracy was again higher overall for the HCS (p<0·0001); sensitivity was 57% (36–76) for 
the HCS and 45% (95% CI 12–83) for clinical assessment, but speciﬁ city was 99·6% (95% CI 95–99·9) versus 92% 
(62–99). Combining clinical assessment and the HCS could result in higher sensitivity (anaemia: 91% [95% CI 
81–96]); severe anaemia 83% (33–98), but at the expense of speciﬁ city (anaemia: 59% [35–79]; severe anaemia 90% 
[40–99]). Individual studies were highly heterogeneous but pooled results did not diﬀ er substantially in a series of 
sensitivity analyses for indicators of study robustness. 
Interpretation In so-called real-life primary health-care conditions, HCS can signiﬁ cantly reduce misdiagnosis of 
anaemia compared with clinical assessment alone. Future research is required to optimise training, and assess 
clinical outcomes and cost-eﬀ ectiveness.
Funding None.
Copyright © Marn et al. Open Access article distributed under the terms of CC BY.
Introduction
Anaemia is a major global cause of maternal, perinatal, 
and child mortality. Additionally, it causes low 
birthweight, impaired or delayed child physical and 
mental development, and an increased susceptibility to 
infections,1 and contributes greatly to economic loss 
due to reduced productivity of workers.2 About 
1·62 billion people are aﬀ ected.1 Most are non-pregnant 
women (468·4 million), preschool age children 
(293·1 million), and pregnant women (56·4 million) 
predominantly in low-income countries, where 
prevalence rates are up to ﬁ ve times higher than in 
high-income countries and are inversely correlated 
with economic status.3,4
In these low-income societies, iron deﬁ ciency anaemia 
is believed to account for about 50% of all cases of 
anaemia,5 but other causes are frequent and often co-exist, 
including malnutrition, micronutrient deﬁ ciencies, 
parasitic infections, other chronic inﬂ ammatory 
conditions, or hereditary haemoglobinopathies.3
Accurate quantitative point-of-care diagnostic tests are 
able to conﬁ rm the diagnosis of anaemia through 
measurement of a decreased amount of red blood cells or 
decreased haemoglobin concentration in the blood,6 but 
these are not suitable in most primary health-care 
settings with very low resources, because they either 
require constant quality control by trained staﬀ , use toxic 
or expensive reagents and consumables, or depend on an 
electricity supply.7
Diagnosis is thus often based on clinical signs alone 
such as conjunctival, palmar, and nailbed pallor. None of 
these signs, whether combined or singly, yield an 
acceptable diagnostic accuracy.8 This leaves many cases 
undetected and untreated and also poses the risk of 
unnecessary and potentially harmful blood transfusions, 
increasing the risk of transmission of blood-borne 
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pathogens, and wasting resources in case of mis-
diagnosed severe anaemia.
In response to the need for a “simple, cheap, and 
robust device to measure haemoglobin by health workers 
outside the laboratory”9,10 the WHO Haemoglobin Colour 
Scale (HCS) was developed and has been produced and 
distributed under licence agreement by Copack 
(Oststeinbek, Germany) since 2001.10–12 The scale 
comprises a small card of six shades of red (lighter to 
darker), each representing a haemoglobin concentration 
of 40 g/L, 60 g/L, 80 g/L, 100 g/L, 120 g/L, and 140 g/L, 
respectively. A drop of blood absorbed onto a standardised 
chromatography ﬁ lter paper is compared with the colour 
scale, allowing assessment of the patient’s haemoglobin 
concentration, including an estimation of intermediate 
results, in 10 g/L steps.13 
The usefulness of the device in practice has been 
disputed,14,15 but in 2005 a systematic review of 14 studies 
showed that, under ideal conditions, the HCS might 
improve diagnosis of mild and moderate anaemia with 
reasonable accuracy (sensitivities from 85% to 99% and 
speciﬁ cities from 91% to 100% in ﬁ ve laboratory-based 
studies).16 Ideal conditions are deﬁ ned as studies taking 
place in a laboratory setting, including trained laboratory 
staﬀ  operating or supervising the HCS measurements 
after intensive training, from blood samples of hospital 
populations or blood donors. The diagnostic accuracy 
tended to be lower in the four so-called real-life studies 
(sensitivities 76–88%, apart from one outlier, and 
speciﬁ cities from 41% to 100%), leading to the conclusion 
that further research was needed to assess the usefulness 
of the HCS in real-life situations. Real life conditions are 
deﬁ ned as studies that were carried out in patient 
populations attending routine primary health clinics or 
public schools, with the HCS undertaken by primary 
health-care workers or a person with comparable skills or 
training. Only a minority (5 of 14) compared the accuracy 
of HCS with clinical diagnosis. We are aware of no 
systematic reviews of the performance of HCS since 
2005, although additional “real life” studies have been 
published. 
We aimed to do an updated systematic review to assess 
the accuracy of the HCS to diagnose anaemia and severe 
anaemia in resource-poor primary health-care settings 
compared with the accuracy of diagnosis by clinical 
assessment, wherever such data are available. 
Methods
Search strategy and selection criteria
Following PRISMA guidelines, we searched the 
electronic databases MEDLINE, EMBASE, SCOPUS, 
Web of Science, Cochrane library, CINAHL plus, Popline, 
Reproductive Health Library, TRIP Database, ADOLEC, 
BDENF, DESASTRES, HISA, MedCarib, LILACS, 
IMEMR, IMSEAR, WPRIM, and Google Scholar, all 
from inception up to Nov 14, 2014. To increase sensitivity 
of the search strategy,17 we searched only the keywords 
“haemoglobin colour scale” without any ﬁ lters using 
alternative spellings in English, Spanish, and French. A 
citation search on “Critchley and Bates 2005 systematic 
Research in context
Evidence before the study
The WHO Haemoglobin Colour Scale (HCS) became 
commercially available in 2001 as an instrument for health-care 
workers in resource-poor settings, who usually have to base the 
diagnosis of anaemia on signs and symptoms, to quantitavely 
assess the anaemia status of their patients. The ﬁ rst and only 
systematic review to date to assess the diagnostic accuracy of 
the HCS was published in 2005, which included 14 studies, but 
most of these were laboratory-based with only four taking place 
in primary care in low-income settings, under which the HCS is 
supposed to be used in practice. The reported estimates of 
diagnostic accuracy from this 2005 review were very 
heterogeneous (sensitivity 75–97% and speciﬁ city 41–98% for 
the detection of anaemia), and were less accurate in the 
four ﬁ eld studies (sensitivity 76–88%; speciﬁ city 41–100%). 
The authors did not compute summary estimates from 
individual studies, except for the ﬁ ve laboratory studies.
Added value of this study
We restricted our systematic review to real life studies (n=14), 
identifying ten more than available at the time of the previous 
review. We were also able to compare the performance of the 
HCS directly against the diagnosis of anaemia by clinical signs, 
because most studies directly compared these two tests. 
This is important because clinical assessment is the standard 
procedure to diagnose anaemia in most primary health-care 
settings in low-income countries. We also estimated diagnostic 
accuracy for simultaneous testing (HCS and clinical signs). 
Despite heterogeneous outcomes, we undertook meta-analysis 
of individual studies using the bivariate random eﬀ ects model, 
and we used an evidence informed tool (QUADAS 2) for the 
assessment of the methodological quality of studies, allowing a 
series of sensitivity analyses.
Implications of all the available evidence
There is sound evidence that the HCS can improve the accuracy 
of diagnosis of anaemia and severe anaemia by primary 
health-care workers under resource-poor conditions. This ﬁ nding 
is consistent in a variety of sensitivity analyses accounting for 
study quality and threshold eﬀ ects. The HCS is signiﬁ cantly more 
sensitive for the diagnosis of anaemia than assessment of clinical 
signs, and the improvement in sensitivity could be clinically 
important in practice. Evidence concerning how training and 
supervision might aﬀ ect the overall performance of the device, 
as well as its cost-eﬀ ectiveness in reducing anaemia-related 
mortality and morbidity in practice, is lacking.
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review16” was done in Medline+Embase (Ovid), Scopus, 
Web of Science, Cinahl plus, and Google scholar. Both 
authors independently screened the titles and abstracts 
of all records retrieved and checked the reference lists of 
eligible articles for further studies; any disagreements 
were resolved by discussion (appendix p 1).
We included all studies comparing the diagnostic 
accuracy of the HCS with any reference method (gold 
standard) to diagnose anaemia under real life conditions 
as deﬁ ned before. There were no restrictions based on 
sample size, location, background morbidities, or 
anaemia prevalence. Studies done in hospitals, 
laboratories, or blood banks were excluded because they 
are not generalisable towards primary health-care in low-
resource settings.
Data extraction and quality assessment
Both authors independently extracted data including the 
main study outcomes, study characteristics, and quality-
related information based on WHO recommendations 
for HCS evaluations (appendix p 2).12 
We assigned tailored quality-relevant criteria to the 
domains “patient selection”, “index test”, “reference 
standard test”, and “ﬂ ow and timing”, as proposed in the 
QUADAS-2 instrument18 and applied customised 
signalling questions (table 1) to each individual study to 
judge whether the risk of bias and applicability concerns 
to our review objectives were either “high” or “low”. The 
rating “unclear” was only used when the publication did 
not report quality-relevant data, when the inter-rater 
reliability was not assessed, or if only one operator did all 
HCS readings. Again, both authors independently 
extracted data for all these aspects of quality using a 
standardised form. Any disagreements were resolved by 
discussion between authors.
Statistical analyses
Both authors independently extracted the study outcomes 
for true positive, true negative, false positive, and false 
negative test results into 2 × 2 tables. The haemoglobin 
cut-oﬀ  level in children aged 6–59 months and during 
pregnancy for diagnosing anaemia was 110 g/L and for 
diagnosing severe anaemia was 70 g/L according to WHO 
recommendation.19 Studies with a diﬀ erent threshold for 
anaemia and severe anaemia were included in the meta-
analysis, but excluded in a sensitivity analysis. We 
assessed heterogeneity between studies through creation 
of forest plots and summary ROC curves.
Overall summary estimates
We used the bivariate random eﬀ ects model to combine 
data across all included studies. This model analyses pairs 
of sensitivity and speciﬁ city estimates jointly, accounting 
for possible correlation between both measures within 
(using a random eﬀ ects model) and between studies 
(assuming normal distribution), hence preserving the two-
dimensional nature of the original data.20 We pooled data 
for the HCS and clinical assessment separately. In a series 
of sensitivity analyses, we excluded diﬀ erent subsets of 
studies to explore whether the exclusion of studies with 
high risk of bias, studies that did not adjust for several 
readings of HCS results from the same patient, and studies 
using diﬀ erent cut-oﬀ s for anaemia and severe anaemia 
would aﬀ ect the pooled accuracy estimates. We then also 
repeated analyses restricted to the studies that compared 
the HCS directly with clinical diagnosis, to assess whether 
confounding by study was aﬀ ecting comparisons.
Comparison of the diagnostic accuracy
We compared the diagnostic accuracy of the HCS with 
clinical diagnosis in a meta-regression analysis (adding 
test as a covariate), allowing for covariance both between 
and within these two “tests”. Again, we used a bivariate 
random eﬀ ects model. We accounted for the correlation 
expected when two diﬀ erent tests take place in the same 
study population, and also tested whether the variances 
of the random eﬀ ects diﬀ ered between tests. For severe 
anaemia, this full model did not converge due to the 
smaller number of studies. We thus entered the type of 
“test” as a covariate with random eﬀ ects; an approach 
that has been shown to produce similar results,21 but with 
the limitation that we can only test for overall diﬀ erences 
in diagnostic accuracy rather than specifying whether it 
is the expected sensitivities or speciﬁ cities that diﬀ er. We 
undertook these models in all studies initially and then 
only in those studies that examined the performance of 
both methods. This also allowed us to estimate a pooled 
accuracy for simultaneous testing, which we assumed to 
be routine practice.
Meta-regression analysis
Using the same bivariate random eﬀ ects model, we 
undertook meta-regression analysis with the addition of 
covariates in sequence to assess whether the following 
variables could explain any of the heterogeneity between 
studies: (1) level of training (greater or less than half a 
See Online for appendix
Risk of bias Applicability concerns
Patient 
selection
Was a consecutive or randomised sample of 
cases enrolled
Did the study avoid inappropriate exclusions
Did included patients match the target 
population
Index test Was the WHO certiﬁ ed HCS kit used
Were the HCS results interpreted without the 
knowledge of the reference test results
Were the results of HCS readings reliable across 
diﬀ erent raters
Did the HCS operator match the review’s 
“real life” objective
Was the training appropriate for resource-
poor situations (at least 1 h, at most 1 day)
Was the cut-oﬀ  for anaemia according to 
WHO recommendations (haemoglobin 
<110 g/L)
Reference 
test
Was the reference test likely to correctly 
diagnose anaemia
Did the reference test allow the assessment 
of the HCS accuracy
Flow and 
timing
Was the sampling of HCS and reference test 
concurrent
..
HCS= Haemoglobin colour scale.  
Table 1: Signalling questions for risk of bias and applicability judgement (QUADAS-2) by domain
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day); (2) type of reference test (standard laboratory test or 
point-of-care test); (3) whether both the HCS and reference 
test used the same type of blood sample (ie, both used 
capillary blood or both used venous blood) or a diﬀ erent 
sample; (4) the population type (women or children); (5) 
anaemia prevalence (40% or higher compared with less 
than 40%). In this meta-regression, we assumed that 
training levels were “low” for the four studies that did not 
report this and that the type of blood sample was diﬀ erent 
for the three studies that did not state this clearly. 
Data were analysed with Review manager version 5.3 
and STATA 12 statistical software packages metandi, 
gllamm, and xtmelogit for meta-analysis and meta-
regression modelling (appendix p 3).20,22 
Role of the funding source
There was no external funding for this study. The 
funding institution of JC had no role in the design and 
development, data extraction, analysis and interpretation 
of the data, or preparation, review, or approval of the 
paper. HM had full access to all data. HM and JC both 
had the decision to submit for publication.
Results
Of 141 records screened for eligibility based on titles and 
abstracts, 98 papers were excluded based on titles and 
abstracts, and 43 full-text articles were assessed for 
eligibility (ﬁ gure 1; appendix p 4). 29 articles were 
excluded because they did not meet the previously deﬁ ned 
real-life inclusion criteria: 14 were undertaken in blood 
banks, eight in hospitals, one in a laboratory, three had a 
mixed ﬁ eld or laboratory design, and two did not report 
diagnostic accuracy data. For one congress abstract23 
information about whether it was ﬁ eld or laboratory 
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 Figure 1: Study selection
HCS=Haemoglobin colour scale.
389 records from search for “HCS” 61 records from citation search 
“Critchley and Bates 2005 
systematic review”16
141 records and abstracts screened
141 records after removing duplicates 
43 full-text articles assessed for eligibility
14 studies included in qualitative synthesis
14 studies included in quantitative synthesis 
(meta-analysis)
98 records excluded
67 not concerned with HCS
7 diagnostic accuracy not tested
15 reviews and overviews
6 letters and comments
1 HCS training only
1 HCS reliability only
1 new digital HCS device
29 full-text articles excluded
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1 congress abstract only: unclear 
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based could not be obtained (appendix p 8). 14 real-life 
studies remained and are included in this review.24–37 
Five of the 14 included studies were done in low-income 
countries and nine in lower middle-income countries: 
seven in sub-Saharan Africa, one in upper Egypt, three in 
India, two in Sri Lanka, and one in Indonesia. All but 
two25,28 were located in rural areas (table 2). Two studies 
were embedded into larger morbidity surveys,32,35 and one 
study retrospectively investigated the use of HCS as part 
of a general survey of quality of primary health-care 
services in Sri Lanka.27 Two studies examined patients 
attending hospitals and primary health-care facilities in 
rural communities.29,31 In both cases only the data from 
the ﬁ eld studies were included in this review. One study 
examined both children and pregnant women.29 For 
practical reasons we regarded these data as two separate 
studies: one in children (Lindblade 2006c) and the other 
one in pregnant women (Lindblade 2006p).
Seven studies24,26,29,30,33,35,37 included children (aged from 
neonates to 11 years), seven studies enrolled pregnant 
women25,27–29,31,32,36 and one included women of reproductive 
age irrespective of their pregnancy status.34
The absolute range of anaemia prevalence was 2–83% 
(median 58%). Only 11 of 15 studies assessed severe 
anaemia; in two of these studies no cases were found 
either by HCS or the reference test.26,27 In the remaining 
nine studies with available data, 20% was the highest 
prevalence reported in one outlier;31 in the remaining 
studies prevalence of severe anaemia varied between 
0·6% and 10% (median 2%). 
Sample sizes ranged between 101 and 1529. In 
two studies24,36 the samples were read more than once 
by diﬀ erent assessors. We report main results excluding 
these two studies because they inappropriately analysed 
all ratings of the scale, rather than patients assessed 
(appendix p 3).
Training intensity varied widely from 1 h24 to 2 days,28,31 
including one case in which the main study was only 
started after two raters had reached excellent agreement 
in a preliminary training pilot.33 Six studies did not report 
any information about training.25–27,32,35,37
Nine studies used capillary blood samples for the HCS 
test,24,26,28,29,31,34–36 three studies did not report which kind of 
samples were used,25,27,30 one used venous blood for both 
the HCS and the reference test,33 and one used umbilical 
cord blood at birth and capillary blood in the follow-up for 
both tests.37
Ten studies used the same kind of sample for both 
tests,24,26,28,29,31,33–35,37 in four studies venous blood samples 
for the reference test were tested in distant 
laboratories,27,32,33,36 two of these against capillary blood 
samples for the HCS.32,36 In three studies, the origin of 
the blood sample was not disclosed for either one or 
both tests.25,27,30
Risk of bias Applicability concerns
Patient selection Index test Reference 
test*
Flow and 
timing†
Patient 
selection‡
Index test Reference 
test§
Randomisation 
or consecutive  
cases
No 
inappropriate 
exclusions
WHO 
certiﬁ ed 
HCS¶
Blinding 
HCS vs 
reference 
test
Reliability 
of HCS 
readings
HCS 
operator 
matches 
review 
objective
Training 
intensity at 
least 1 h, at 
most 1 day
WHO 
according 
cut-oﬀ  
(110 g/L)
van den Broek 
(1999)
Unclear Low Low Low Low Low Low Low Low Low Low Low
Montresor (2000) Unclear Low Low Low Low Low Low Low High Low Low Low
Barduagni (2003) Low Low Low Low Unclear Low Low Low Low Unclear High Low
Montresor (2003) Unclear Low Low Low Low Low Low Low Low High Low Low
Gies (2003) Low Low Low Low Low Low Low Low Low High Low Low
Lindblade (2006c) Low Low Low Unclear Low Low Low Low Low Low Low Low
Lindblade (2006p) Low Low Low Unclear Low Low Low Low Low Low Low Low
van Rheenen (2007) Low High Low Low Unclear Low Low High High Unclear High Low
Sinha (2008) Low Low Low Low Unclear High Low Low High Unclear Low High
Rusmawatiningtyas 
(2009)
Low Unclear Low Low Low Low Low Low High High High Low
Bala (2012) Low Low High Low Low High Low Low Low Unclear Low High
Prathapan (2011) Low High Unclear Low Unclear Low Low Low Low Unclear Low Low
Chathurani (2012) High High Unclear Low Unclear Low Low Low Low Unclear Low Low
Aldridge (2012) Low Low Low Low Low Low Low Low Low Low Low Low
Shah (2014) Low Low Low Low Unclear Low Low Low Low Low High Low
HCS=Haemoglobin colour scale. *Test likely to correctly diagnose anaemia. †Concurrent sampling of HCS and reference test. ‡Included patients match the target population. §Test allows assessment of HCS 
accuracy. ¶The Haemoglobin Colour Scale from the Indian manufacturer Kruise Path (Ahmedabad, India) is not certiﬁ ed by the original German manufacturer Copack GmbH (appendix p 2 gives more details).
Table 3: QUADAS-2 quality judgments about each domain for each included study
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HemoCue (HemoCue AB, Ängelholm, Sweden) from 
capillary blood samples was the most frequent reference 
standard test (n=9) for practical reasons. Two studies 
used inappropriate point-of-care methods as reference 
tests: Sahli’s haemometer25 and the ﬁ lter paper 
cyanmethaemoglobin method.35 In ten studies, the 
investigators directly compared the performance of 
clinical assessment for anaemia with the HCS 
(table 2).24,25, 27–31,35,36
We detected high risk of bias in ﬁ ve studies25,27,32,35,37 and 
had severe applicability concerns about nine of the 
14 studies. In all but two studies24,28 incomplete reporting 
demanded an unclear rating in one or more quality 
relevant domains (ﬁ gure 2; table 3; appendix p 10, 14).
Anaemia Severe anaemia
Haemoglobin colour scale Clinical assessment Haemoglobin colour scale Clinical assessment
All studies
Participants (studies) 7805 (15) 6413 (10) 6663 (9) 5476 (8)
Prevalence 0·58 (0·12–0.83) 0·70 (0·15–0·83) 0·024 (0·006–0·2) 0·02 (0·006–0·2)
Sensitivity (%; 95% CI) 77 (64–86) 52 (36–67) 54 (36–71) 45 (12–83)
Speciﬁ city (%; 95% CI) 79 (61–90) 75 (56–88) 99·5 (98–99·9) 92 (62–99)
PV+ 0·84 0·83 0·73 0·11
PV- 0·71 0·40 0·99 0·99
All studies without multiple HCS testing*
Participants (studies) 5813 (13) 6413 (10) 4547 (7) 5476 (8)
Prevalence 0·52 (0·12–0·83) 0·70 (0·15–0·83) 0·025 (0·013–0·2) 0·02 (0·006–0·2)
Sensitivity (%; 95% CI) 80 (68–88) 52 (36–67) 57 (36–76) 45 (12–83) 
Speciﬁ city (%; 95% CI) 80 (59–91) 75 (56–88) 99·6 (95–99·9) 92 (62–99)
PV+ 0·81 0·83 0·79 0·11
PV- 0·79 0·40 0·99 0·99
Studies without high risk of bias† or multiple HCS testing*
Participants (studies) 4322 (8) 4977 (7) 3646 (5) 4575 (6)
Prevalence 0·62 (0·12–0·83) 0·71 (0·15–0·83) 0·036 (0·024–0·2) 0·028 (0·006–0·2)
Sensitivity (%; 95% CI) 84 (70–92) 46 (34–58) 68 (55–79) 62 (22–90)
Speciﬁ city (%; 95% CI) 76 (43–93) 74 (61–83) 99 (95–99·8) 80 (46–95)
PV+ 0·85 0·81 0·72 0·08
PV- 0·74 0·36 0·99 0·99
All comparative studies‡ (HCS vs clinical assessment) without multiple HCS testing*
Participants (studies) 4564 (8) 6413 (10) 4046 (6) 5476 (8)
Prevalence 0·72 (0·15–0·83) 0·70 (0·15–0·83) 0·03 (0·013–0·2) 0·02 (0·006–0·2)
Sensitivity (%; 95% CI) 79 (64–88) 52 (36–67) 53 (27–78) 45 (12–83) 
Speciﬁ city (%; 95% CI) 77 (52–91) 75 (56–88) 99·6 (93–99·9) 92 (62–99)
PV+ 0·90 0·83 0·80 0·11
PV- 0·59 0·40 0·99 0·99
All studies with common threshold for anaemia (Hb <110 g/L) and severe anaemia (Hb <70 g/L)§
Participants (studies) 6781 (11) 6413 (10) 4547 (7) 4045 (6)
Prevalence 0·70 (0·15–0·83) 0·70 (0·15–0·83) 0·025 (0·013–0·2) 0·03 (0·013–0·2)
Sensitivity (%; 95% CI) 74 (60–84) 52 (36–67) 57 (36–76) 54 (16–88)
Speciﬁ city (%; 95% CI) 77 (59–89) 75 (56–88) 99·6 (95–99·9) 91 (44–99)
PV+ 0·88 0·83 0·79 0·16
PV- 0·56 0·40 0·99 0·99
Data are n (n), median (range), unless otherwise stated. HCS=Haemoglobin colour scale. PV+=positive predictive value. PV-=negative predictive value. *Aldridge (2012)24 and 
van den Broek (1999)36 allowed multiple observers to assess the same HCS specimen from some of the participants, see main text for details. We report this result as the main 
pooled analysis since it only includes statistically unbiased studies. The diﬀ erence between the sensitivity of the HCS and clinical assessment to diagnose anaemia is 
statistically signiﬁ cant (p=0·008). The diﬀ erence between the speciﬁ city of  the HCS and clinical assessment to diagnose anaemia was not statistically signiﬁ cant (p=0·825). 
For severe anaemia the overall diagnostic accuracy of the HCS is signiﬁ cantly higher than for clinical assessment (p<0·0001). †van Rheenen (2007),37 Sinha (2008),35 
Bala (2012),25 Prataphan (2011),32 and Chathurani (2012)27 were excluded for high risk of bias. See appendix p 14 for details. ‡Barduagni (2003),26 van Rheenen (2007),37 
Rusmawatinigtyas (2009),33 Prataphan (2011),32 and Shah (2014)34 did not assess anaemia by clinical assessment. §The following studies used thresholds diﬀ erent from the 
WHO recommendations in school-age children and pregnant women for the diagnosis of anaemia (<110 g/L): Barduagni (2003;26 <120 g/L), van Rheenen (2007;37 diﬀ erent 
age-speciﬁ c thresholds for newborn babies), Rusmawatinigtyas (2009;33 (<115 g/L), and severe anaemia (<70 g/L): van den Broek (1999;36 <60 g/L), Aldridge (2012;24 
<50 g/L). Shah (2014)34 tested pregnant and non-pregnant women at the same threshold (<120 g/L).
Table 4: Sensitivity analysis of pooled estimates for HCS and clinical assessment accuracy 
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The diagnostic accuracy of the HCS to diagnose 
anaemia varied widely across individual studies; 
sensitivities ranged from 33% to 96% and speciﬁ cities 
from 14% to 100% (ﬁ gure 3). 
The meta-analysis from 13 statistically unbiased 
studies—ie, excluding those with multiple counts from 
the same sample24,36—showed a higher pooled sensitivity 
of 80% (95% CI 68–88) for the HCS compared with 52% 
(36–67) for clinical assessment (p=0·008; ﬁ gure 4). 
Pooled speciﬁ cities were similar at 80% (95% CI 59–91) 
for the HCS and 75% (56–88) for clinical assessment 
(p=0·8250). 
When we included the eight statistically unbiased 
studies (without multiple HCS testing) that explicitly 
compared the HCS with clinical assessment within the 
same study to diagnose anaemia (median anaemia 
prevalence: 70% [range 15–83], the pooled results were 
very similar: HCS sensitivity 79% (95% CI 64–88) vs 
clinical assessment sensitivity 52% (36–67; p=0·0289) 
and HCS speciﬁ city 77% (52–91) vs clinical assessment 
speciﬁ city 75% (56–88; p=0·8649). Whether we included 
all studies or excluded studies that had an unacceptable 
number of exclusions or withdrawals of participants, did 
not use an appropriate reference standard, used a non-
certiﬁ ed version of the HCS, or a cut-oﬀ  for anaemia that 
diﬀ ered from 110 g/L, made little diﬀ erence to the results 
(table 4). 
For the diagnosis of severe anaemia, the diagnostic 
accuracy across individual studies showed a similar 
heterogeneity (speciﬁ cities 19% to 91%; sensitivities 13% 
to 98%; ﬁ gure 5). In the meta-analysis, the HCS again 
performed better (p<0·0001), yielding 57% (95% CI 
36–76) sensitivity compared with 45% (12–83) by clinical 
assessment (ﬁ gure 6). Speciﬁ city for the HCS was 99·6% 
(95% CI 95–99·9)—higher than the estimate of 92% 
(62–99) for clinical assessment; again we saw little 
diﬀ erences in the sensitivity analysis (table 4). 
In practice, it is likely that primary health-care workers 
would use both the HCS and clinical assessment to 
diagnose anaemia, resulting in a net gain in sensitivity. 
In studies examining both methods, the sensitivity of a 
positive result on either the HCS or clinical assessment 
for anaemia rose to 91% (95% CI 81–96) after excluding 
studies with inappropriate multiple assessments24,36 and 
an unacceptable amount of missing HCS values.27 
However, to rule out anaemia, results from both methods 
would have to be negative, which leads to a net loss of 
speciﬁ city to 59% (95% CI 35–79) for simultaneous 
testing.38 For severe anaemia, simultaneous testing 
would yield a pooled net sensitivity of 83% (95% CI 
33–98) in the six comparative studies without multiple 
assessments for the HCS, whereas the speciﬁ city would 
decrease to 90% (95% CI 40–99).
Meta-regression analyses did not show a signiﬁ cant 
eﬀ ect of the covariates population group, anaemia 
prevalence, reference test, training quantity, and source 
of blood sample (table 5; appendix p 15), although this 
could be due to incomplete reporting—eg, for training, 
or small numbers of studies (with use of appropriate 
laboratory reference tests).
Discussion
We systematically reviewed the literature to assess the 
accuracy of the HCS to diagnose anaemia and severe 
anaemia when used by primary health-care workers in 
resource-poor settings, and compared this with the 
accuracy of assessment by clinical signs alone. 
Publication bias can never be ruled out completely, but 
the search was comprehensive and no studies were 
excluded due to language of publication. 
We have identiﬁ ed substantial heterogeneity of 
accuracy outcomes between the selected 14 studies, with 
sensitivities ranging from 33% to 96% and speciﬁ cities 
from 14% to 100% for the HCS. We could not fully 
account for this heterogeneity, possibly because of the 
small number of studies or incomplete reporting of key 
Sensitivity Speciﬁ city p value
Prevalence of anaemia
Very high (≥40%) 79 69 0·3068
Low to moderate (<40%) 68 90 ..
Population
Children 83 93 0·3153
Women 66 68 ..
Training*
High (≥0·5 day) 78 74 0·8091
Low (<0·5 day) 74 83 ..
Reference test
Point-of-care test† 78 76 0·5897
Laboratory test‡ 66 88 ..
Blood sample§
Same 79 84 0·2721
Diﬀ erent 66 67 ..
*We did the meta-regression analysis for training under the assumption that 
studies without information on training had less than half day (low) of training. 
†Point-of-care tests included: HemoCue, ﬁ lter paper cyanmethaemoglobin 
method, and Sahli’s haemometer. ‡Laboratory tests were done in clinical 
laboratories and included: electronic coulter counter, Hematology Analyzer 
(HmX), spectrometry method, and laboratory-based cyanmethaemoglobin 
method. §Blood samples for the HCS and the reference test had either the same 
origin (capillary, venous, or umbilical cord) or diﬀ erent sources (eg, capillary vs 
venous). In cases where it was unclear whether the origin was the same, we 
assumed that the sources of the blood sample were diﬀ erent.
Table 5: Meta-regression analysis of the eﬀ ect of covariates on HCS 
accuracy by potential sources of heterogeneity 
Figure 2: QUADAS-2 judgments about each domain presented as percentages across included studies
0 25 50 75 100 0 25 50
Risk of bias (%) Applicability concerns (%)
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methods. Heterogeneity might be explained by 
diﬀ erences in the quality of methods, anaemia 
prevalence, training intensity, the choice of the reference 
test, and the source of the blood sample.
Whether the use of diﬀ erent blood samples (capillary, 
venous, or umbilical cord) between studies could have 
been a reason for heterogeneity is unclear. Discrepancies 
between the standard test and the HCS might have been 
exaggerated by the fact that the origins of the blood 
samples also varied within at least two studies.32,36 Transport 
conditions or suboptimal storage could potentially have 
damaged blood specimens in four studies27,32,33,36 in which 
the reference test was done in a distant laboratory, although 
this was not mentioned in the studies.
Intensity of training varied substantially and was poorly 
reported. We could not identify a relation between 
training and accuracy outcomes. However, during HCS 
development, it was shown that trainees’ performance 
improved signiﬁ cantly with further familiarisation, even 
after receiving an initial 30 min demonstration.10 
Consequently, the original training protocol required two 
training sessions of about 2 h on 2 consecutive days. 
Others have shown inter-rater variations even if adhering 
to the protocol39 and some have suggested that easy-to-
read instructions, cartoons, and coloured test strips might 
improve accuracy.40 Unfortunately, once the HCS became 
commercially available, no further evidence was collated 
to reﬁ ne the training protocol, possibly explaining the 
variation in training across the included studies.
Although laboratory-based methods remain the gold 
standard for the measurement of haemoglobin,5 most 
studies used the HemoCue, which is easy to use, battery 
powered, and requires only a small amount of blood 
because of the use of microcuvettes. Although its accuracy 
compared against the gold standard is good, venous and 
arterial samples yield more accurate results than those 
obtained from capillary blood5,7,41 and high humidity 
might alter the functionality of the microcuvettes.42 
Figure 3: Forest plots of all studies diagnosing anaemia by HCS and clinical assessment
HCS=Haemoglobin colour scale.  
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Figure 4: Summary ROC plot of studies diagnosing anaemia by HCS and clinical assessment 
Note: Aldridge (2012) and van den Broek (1999) excluded from summary estimate for the HCS assessment for allowing observers to assess the same HCS specimen 
from some of the participants, see main text for details. The weights for analysis are inverse variance, size points of individual studies represent sample sizes. 
HCS=Haemoglobin colour scale. 
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It was also unavoidable that our selection criteria allowed 
four studies to be included that did not completely comply 
with the real-life approach with respect to the person who 
did the HCS assessment. Four studies used cut-oﬀ s for the 
deﬁ nition of anaemia that were not in line with WHO 
recommendations19 and we identiﬁ ed ﬁ ve studies that had 
introduced a high risk of bias, which we handled by 
excluding them in a sensitivity analysis (table 4). 
Two studies introduced statistical bias including multiple 
counts from the same sample in their analysis, which 
obliged us to exclude them from the summary estimates, 
but in most studies (n=12) the possibility of bias was hard 
to assess due to incomplete reporting of methods.
Despite these limitations, our pooled estimates suggest 
that in real-life circumstances the HCS signiﬁ cantly 
improves the accuracy of the diagnosis of anaemia. By 
clinical examination alone, 48% of patients with mild-to-
moderate anaemia would be missed. The HCS alone 
might signiﬁ cantly reduce this proportion to 20%. 
Although in study settings both methods were assessed 
independently, in reality they would be combined as 
simultaneous tests in addition to the patient’s history. We 
would expect a net gain in sensitivity from 80% (HCS) and 
52% (clinical assessment) for the single methods to 91% if 
the diagnosis of anaemia was considered with either or 
both methods being positive (severe anaemia: net 
sensitivity 83%). However, the potential cost of use of both 
methods simultaneously would be a loss of speciﬁ city.
The public health relevance is best shown by an 
example: 80% of Malawi’s 15 million people live in rural 
areas; among these are 6·5 million women, of whom 
2·7 million have anaemia (anaemia prevalence 45%). 
Nearly every second woman—ie, 1·3 million—would 
have the correct diagnosis missed through assessment of 
the clinical signs only. The HCS alone would reduce the 
number of underdiagnosed women from 1·3 million to 
0·5 million, hence 800 000 additional women would 
receive the appropriate diagnosis and potentially correct 
care. If use of both clinical assessment and HCS was 
combined, more than 1 million additional women would 
be diagnosed correctly. 
Unfortunately, the reduction of underdiagnosis 
diminishes when anaemia becomes severe. In this case, 
the HCS leaves 43% undetected, whereas the assessment 
of clinical signs leaves 55% undetected. The HCS is able to 
signiﬁ cantly reduce the number of those falsely diagnosed 
with severe anaemia (0·4% vs 7·6%), hence preventing a 
large number of patients from unnecessary and potentially 
harmful blood transfusions or cost-intensive referrals. 
Both methods do not signiﬁ cantly diﬀ er between the 
amount of non-anaemic patients being wrongly 
diagnosed with mild-to-moderate anaemia, which would 
be the case by clinical assessment in 25% and with the 
HCS in 20%. Overdiagnosis of mild-to-moderate 
anaemia is predominantly an economic issue. It 
increases expenses for unneeded supplementation 
therapy or unnecessary further diagnostic investigations 
in settings where resources are already poor.
However, one advantage of the HCS is that it delivers 
quantitative results, whereas the clinical assessment is 
purely qualitative. Although the available studies do not 
allow an inference about the eﬀ ect of the knowledge of 
Figure 6: Summary ROC plot of studies assessing severe anaemia by HCS and clinical assessment
Note: Aldridge (2012) and van den Broek (1999) excluded from summary estimate for the HCS assessment for allowing observers to assess the same HCS specimen 
from some of the participants, see main text for details. The weights for analysis are inverse variance, size points of individual studies represent sample sizes. 
HCS=Haemoglobin colour scale. 
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continuous values on clinical decisions, such decisions 
will probably be more strongly aﬀ ected by borderline 
results close to the deﬁ ned thresholds of severe anaemia 
than by the clinical assessment alone. Unfortunately, none 
of the studies assessed the eﬀ ectiveness of the HCS, such 
as the eﬀ ect on clinical outcomes or its cost-eﬀ ectiveness.
Almost 15 years after it became commercially available, 
the HCS remains the most simple to use and aﬀ ordable 
point-of-care device to assess the concentration of 
haemoglobin quantitatively. However, clinical outcomes 
depend on the management decisions made by primary 
health-care workers who have diagnosed anaemia, 
regardless of the method used. The results from the HCS 
are prone to individually erroneous readings by individual 
health-care workers, who in case of discordant results have 
to decide whether to rely on their clinical judgment or the 
HCS. Taking into account the potential clinical and 
economic consequences of misdiagnosis and in view of the 
evidence that the HCS yields a signiﬁ cantly better sensitivity 
and a similar speciﬁ city for mild-to-moderate anaemia, but 
a similarly poor sensitivity and a better speciﬁ city for severe 
anaemia, we recommend that the HCS result should over-
rule the clinical judgment in most cases, but for severe 
anaemia a positive HCS might be over-ruled if clinical 
signs are missing. Whether a short-term follow-up of 
patients with discordant or borderline results would 
improve their clinical outcome remains to be assessed.
Public health decision makers should be aware that the 
use of the HCS might require more training and 
supervision than technically more sophisticated devices. 
To tap the full potential of the HCS, an evidence-based 
standardised training protocol that has to be as short and 
cost-eﬀ ective as possible under the pressure of poor 
resources is urgently needed. Future research should 
also address endpoints beyond the diagnostic accuracy of 
the HCS, such as its potential to reduce morbidity and 
mortality associated with anaemia and the cost-
eﬀ ectiveness of use of the HCS in routine practice.
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